Showing results (81-90 of 283) with videos related to
Sort By:
Pageof 29
Antiviral Therapy|November 13, 2015
Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric miceHiromi Kan, Nobuhiko Hiraga, Michio Imamura, et al.The Journal of General Virology|January 26, 2007
Dual effect of APOBEC3G on Hepatitis B virusChiemi Noguchi, Nobuhiko Hiraga, Nami Mori, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 7, 2015
Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case reportTomokazu Kawaoka, Michio Imamura, Kei Morio, et al.European Journal of Radiology|May 17, 2015
Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary casesTakayuki Fukuhara, Hiroshi Aikata, Hideyuki Hyogo, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 24, 2018
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practiceShinsuke Uchikawa, Tomokazu Kawaoka, Hiroshi Aikata, et al.Journal of Gastroenterology and Hepatology|August 30, 2014
Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathwayYohji Honda, Shoichi Takahashi, Yizhou Zhang, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 7, 2015
Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitusHiromi Kan, Hideyuki Hyogo, Hidenori Ochi, et al.Journal of Gastroenterology|March 5, 2011
Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapyYuko Nagaoki, Hiroshi Aikata, Daisuke Miyaki, et al.Hepato-Gastroenterology|June 6, 2014
Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitusTakayuki Fukuhara, Hideyuki Hyogo, Hidenori Ochi, et al.Journal of Gastroenterology|June 29, 2016
The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver diseaseReona Morio, Hideyuki Hyogo, Masahiro Hatooka, et al.Pageof 29